cambridgesoft -- virtualized pharma in 2020

6
April 2011 John P. McAlister Pistoia Alliance – Virtualized Pharma in 2020

Upload: pistoia-alliance

Post on 11-May-2015

660 views

Category:

Technology


3 download

DESCRIPTION

The Pistoia Alliance Conference in April 2011 included a series of 10-minute "lightning talks" from vendors about what they think pharma will look like in 2020. This presentation was delivered by John P. McAlister of CambridgeSoft.

TRANSCRIPT

Page 1: CambridgeSoft -- Virtualized Pharma in 2020

April 2011 John P. McAlister

Pistoia Alliance – Virtualized Pharma in 2020

Page 2: CambridgeSoft -- Virtualized Pharma in 2020

Page 2

Industry in Throes of Change

Industry business strategies revisited

Cost control is increasingly a decision driver Strategy is in flux at large pharma players

Focus on sales and marketing or continue strong investment in R&D? Network research activities with other pharmas and cross-license IP? Invest in “centers of excellence” (internal or external) or traditional model?

Benefits of small, entrepreneurial research environment

Industry consolidation, reorganization

Industry players, customers & suppliers consolidate and divest Global operations optimized – strategic diversification

Based on markets, costs, resources

Rapid Innovation (science and technology)

‘Omics, diagnostics/patient segregation, new therapeutic strategies Translational medicine reduced to practice

Page 3: CambridgeSoft -- Virtualized Pharma in 2020

Page 3

Information Systems – Enabling Strategic Options

Capture and manage all aspects of research information from the enterprise?

Globally distributed systems will be the norm – likely cloud-based Industry will require fine control of access to system and content Traditional “discipline-focused” systems area insufficient

Link to medical systems to access outcomes information directly

New procedures will be required to protect patient information Assume that each subject will have full genomic information available along with relevant

proteome and metabolome

Capture post-market information to assess and fine-tune product

Incorporate analytical methods that include inference engines, hypothesis generation and analysis platforms

Models are too simplistic for the current range of diseases Multidimensional parameter spaces demand novel methods for analysis and interpretation

Page 4: CambridgeSoft -- Virtualized Pharma in 2020

Page 4

Research Information Systems• Replace paper-based workflows with detailed e-workflows across the full range of life

science business areas

• Apply decision support methods to support research

Chemistry Biology ‘Omic InfoMedical

OutcomesMarket

Surveillance

Searchable DB

Strategic Decisions

Page 5: CambridgeSoft -- Virtualized Pharma in 2020

Page 5

Information Systems – The Future

No single supplier will provide all information systems required by research enterprise

Specialty-based systems are already available across the disciplines Consolidation of closely related suppliers is inevitable, generating powerful large players

Innovative small startups will quickly be targeted for acquisition

Systems implementation will be a major component of the enterprise

Cross-functional team expertise will be the gold-standard of the future Standards-based APIs are essential

Collaborative relationships among major informatics suppliers will be essential for pharma research and development information systems delivery

Page 6: CambridgeSoft -- Virtualized Pharma in 2020

Page 6